Archives of Clinical Infectious Diseases

Published by: Kowsar

Evaluation of the Ability of Malassezia Species in Biofilm Formation

Mahdi Zareei 1 , Shahla Roudbar Mohammadi 1 , * , Shirin Shahbazi 2 , Maryam Roudbary 3 and Zeinab Borjian Borujeni 4
Authors Information
1 Department of Medical Mycology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2 Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
3 Department of Medical Mycology and Parasitology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
4 Department of Medical Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Article information
  • Archives of Clinical Infectious Diseases: August 2018, 13 (4); e62223
  • Published Online: July 31, 2017
  • Article Type: Research Article
  • Received: July 31, 2016
  • Revised: March 11, 2017
  • Accepted: March 14, 2017
  • DOI: 10.5812/archcid.62223

To Cite: Zareei M, Roudbar Mohammadi S, Shahbazi S, Roudbary M, Borjian Borujeni Z. et al. Evaluation of the Ability of Malassezia Species in Biofilm Formation, Arch Clin Infect Dis. 2018 ; 13(4):e62223. doi: 10.5812/archcid.62223.

Abstract
Copyright © 2017, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Figueredo LA, Cafarchia C, Otranto D. Antifungal susceptibility of Malassezia pachydermatis biofilm. Med Mycol. 2013;51(8):863-7. doi: 10.3109/13693786.2013.805440. [PubMed: 23834283].
  • 2. Blankenship JR, Mitchell AP. How to build a biofilm: a fungal perspective. Curr Opin Microbiol. 2006;9(6):588-94. doi: 10.1016/j.mib.2006.10.003. [PubMed: 17055772].
  • 3. Chandra J, Zhou G, Ghannoum MA. Fungal biofilms and antimycotics. Curr Drug Targets. 2005;6(8):887-94. doi: 10.2174/138945005774912762. [PubMed: 16375672].
  • 4. Figueredo LA, Cafarchia C, Desantis S, Otranto D. Biofilm formation of Malassezia pachydermatis from dogs. Vet Microbiol. 2012;160(1-2):126-31. doi: 10.1016/j.vetmic.2012.05.012. [PubMed: 22682201].
  • 5. Cannizzo FT, Eraso E, Ezkurra PA, Villar-Vidal M, Bollo E, Castella G, et al. Biofilm development by clinical isolates of Malassezia pachydermatis. Med Mycol. 2007;45(4):357-61. doi: 10.1080/13693780701225767. [PubMed: 17510859].
  • 6. Larocco M, Dorenbaum A, Robinson A, Pickering LK. Recovery of Malassezia pachydermatis from eight infants in a neonatal intensive care nursery: clinical and laboratory features. Pediatr Infect Dis J. 1988;7(6):398-401. doi: 10.1097/00006454-198806000-00006. [PubMed: 3134645].
  • 7. Mickelsen PA, Viano-Paulson MC, Stevens DA, Diaz PS. Clinical and microbiological features of infection with Malassezia pachydermatis in high-risk infants. J Infect Dis. 1988;157(6):1163-8. doi: 10.1093/infdis/157.6.1163. [PubMed: 3373021].
  • 8. Welbel SF, McNeil MM, Pramanik A, Silberman R, Oberle AD, Midgley G, et al. Nosocomial Malassezia pachydermatis bloodstream infections in a neonatal intensive care unit. Pediatr Infect Dis J. 1994;13(2):104-8. doi: 10.1097/00006454-199402000-00005. [PubMed: 8190533].
  • 9. Chryssanthou E, Broberger U, Petrini B. Malassezia pachydermatis fungaemia in a neonatal intensive care unit. Acta Paediatr. 2001;90(3):323-7. doi: 10.1080/080352501300067712. [PubMed: 11332175].
  • 10. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15(2):167-93. doi: 10.1128/CMR.15.2.167-193.2002. [PubMed: 11932229].
  • 11. Douglas LJ. Medical importance of biofilms in Candida infections. Rev Iberoam Micol. 2002;19(3):139-43. [PubMed: 12825991].
  • 12. Lopez-Ribot JL. Candida albicans biofilms: more than filamentation. Curr Biol. 2005;15(12):R453-5. doi: 10.1016/j.cub.2005.06.020. [PubMed: 15964263].
  • 13. Curvale-Fauchet N, Botterel F, Legrand P, Guillot J, Bretagne S. Frequency of intravascular catheter colonization by Malassezia spp. in adult patients. Mycoses. 2004;47(11-12):491-4. doi: 10.1111/j.1439-0507.2004.01047.x. [PubMed: 15601455].
  • 14. Chandra J, Mukherjee PK, Leidich SD, Faddoul FF, Hoyer LL, Douglas LJ, et al. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res. 2001;80(3):903-8. doi: 10.1177/00220345010800031101. [PubMed: 11379893].
  • 15. Rajendran R, May A, Sherry L, Kean R, Williams C, Jones BL, et al. Integrating Candida albicans metabolism with biofilm heterogeneity by transcriptome mapping. Sci Rep. 2016;6:35436. doi: 10.1038/srep35436. [PubMed: 27765942].
  • 16. Zarei Mahmoudabadi A, Zarrin M, Kiasat N. Biofilm Formation and Susceptibility to Amphotericin B and Fluconazole in Candida albicans. Jundishapur J Microbiol. 2014;7(7). e17105. doi: 10.5812/jjm.17105. [PubMed: 25368806].
  • 17. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun. 2002;70(2):878-88. doi: 10.1128/IAI.70.2.878-888.2002. [PubMed: 11796623].
  • 18. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol. 2001;183(18):5385-94. [PubMed: 11514524].
  • 19. Released I. IBM SPSS Statistics for Windows. 20. Armonk, NY: IBM Corp; 2013.
  • 20. Weiss SJ, Schoch PE, Cunha BA. Malassezia furfur fungemia associated with central venous catheter lipid emulsion infusion. Heart Lung. 1991;20(1):87-90. [PubMed: 1988397].
  • 21. Shparago NI, Bruno PP, Bennett J. Systemic Malassezia furfur infection in an adult receiving total parenteral nutrition. J Am Osteopath Assoc. 1995;95(6):375-7. [PubMed: 7615409].
  • 22. Iatta R, Cafarchia C, Cuna T, Montagna O, Laforgia N, Gentile O, et al. Bloodstream infections by Malassezia and Candida species in critical care patients. Med Mycol. 2014;52(3):264-9. doi: 10.1093/mmy/myt004. [PubMed: 24576998].
  • 23. Plumb JA. Cell sensitivity assays: the MTT assay. Cancer Cell Culture: Methods and Protocols. 2004. p. 165-9.
  • 24. Fischer J, Prosenc MH, Wolff M, Hort N, Willumeit R, Feyerabend F. Interference of magnesium corrosion with tetrazolium-based cytotoxicity assays. Acta Biomater. 2010;6(5):1813-23. doi: 10.1016/j.actbio.2009.10.020. [PubMed: 19837191].
  • 25. Ramage G, Vandewalle K, Wickes BL, Lopez-Ribot JL. Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol. 2001;18(4):163-70. [PubMed: 15496122].
  • 26. Coenye T, Nelis HJ. In vitro and in vivo model systems to study microbial biofilm formation. J Microbiol Methods. 2010;83(2):89-105. doi: 10.1016/j.mimet.2010.08.018. [PubMed: 20816706].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments